| 1 |
35484635 | Trough plasma nevirapine levels, immunologic and virologic responses in composite CYP2B6*6/*18 HIV-infected adult Nigerian patients. | 2022 Jul |
2 |
| 2 |
35512066 | The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana. | 2022 Apr 29 |
1 |
| 3 |
32815870 | Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. | 2021 Jan |
1 |
| 4 |
33758532 | Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana. | 2021 |
3 |
| 5 |
33833550 | Erratum: Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana [Corrigendum]. | 2021 |
1 |
| 6 |
33060725 | Effects of CYP2B6 polymorphisms on plasma nevirapine concentrations: a systematic review and meta-analysis. | 2020 Oct 15 |
3 |
| 7 |
30864294 | Occurrence of CYP2B6 516G>T polymorphism in patients with ARV-associated hepatotoxicity. | 2019 Apr |
4 |
| 8 |
27707991 | Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. | 2017 Jan |
1 |
| 9 |
28187506 | The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. | 2017 Sep |
1 |
| 10 |
26626330 | Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. | 2016 Aug 5 |
1 |
| 11 |
26891286 | Inhibition of CYP2B6 by Medicinal Plant Extracts: Implication for Use of Efavirenz and Nevirapine-Based Highly Active Anti-Retroviral Therapy (HAART) in Resource-Limited Settings. | 2016 Feb 16 |
1 |
| 12 |
27195527 | Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. | 2016 Aug |
2 |
| 13 |
27709010 | Insights into CYP2B6-mediated drug-drug interactions. | 2016 Sep |
1 |
| 14 |
25878720 | Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study. | 2015 |
6 |
| 15 |
26247717 | CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon. | 2015 Oct |
1 |
| 16 |
26348712 | Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients. | 2015 Sep |
5 |
| 17 |
26415139 | A Global Health Diagnostic for Personalized Medicine in Resource-Constrained World Settings: A Simple PCR-RFLP Method for Genotyping CYP2B6 g.15582C>T and Science and Policy Relevance for Optimal Use of Antiretroviral Drug Efavirenz. | 2015 Jun |
1 |
| 18 |
23687222 | Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission. | 2013 Aug 15 |
2 |
| 19 |
23774940 | Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. | 2013 Nov |
1 |
| 20 |
23982262 | Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes? | 2013 Nov |
1 |
| 21 |
24517233 | Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort in Zimbabwe. | 2013 Sep |
1 |
| 22 |
22082652 | Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. | 2012 Jan |
1 |
| 23 |
22111602 | Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. | 2012 Jan |
2 |
| 24 |
22462748 | Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. | 2012 Apr |
1 |
| 25 |
22680342 | Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. | 2012 Jul |
3 |
| 26 |
23104099 | Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians. | 2012 Dec |
2 |
| 27 |
23439719 | Clinical perspectives on human genetic screening to prevent nevirapine toxicity. | 2012 Sep 1 |
1 |
| 28 |
21393201 | Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India. | 2011 Jun |
1 |
| 29 |
21441248 | Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. | 2011 Jun |
3 |
| 30 |
21860339 | Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine. | 2011 Nov |
1 |
| 31 |
20338069 | Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. | 2010 Mar 26 |
4 |
| 32 |
19228205 | Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. | 2009 May |
4 |
| 33 |
19239339 | Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. | 2009 Mar 15 |
2 |
| 34 |
19702527 | Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. | 2009 Sep |
1 |
| 35 |
19812066 | Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. | 2009 Dec |
2 |
| 36 |
18281305 | Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. | 2008 Apr |
1 |
| 37 |
18781911 | CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. | 2008 Sep |
1 |
| 38 |
21197270 | Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors. | 2008 Jan 1 |
1 |
| 39 |
17352764 | Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. | 2007 Mar |
1 |
| 40 |
18090046 | CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. | 2007 Oct 18 |
4 |
| 41 |
17003847 | RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity. | 2006 Sep |
2 |
| 42 |
15864119 | Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. | 2005 Jan |
2 |
| 43 |
14628297 | Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. | 2004 Jan |
1 |